Tumour markers

Details Tumour markers Tumour markers

1999-05-11

2008-07-22

Canella, Karen A. (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C436S064000, C436S501000, C436S506000, C436S507000, C436S536000

Reexamination Certificate

active

07402403

ABSTRACT:
A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigens. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.

REFERENCES:
patent: 4898951 (1990-02-01), Symons
patent: 4937185 (1990-06-01), Webb et al.
patent: 5157020 (1992-10-01), Kay et al.
patent: 5501955 (1996-03-01), Bergman
patent: 5652115 (1997-07-01), Marks et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5747268 (1998-05-01), Herring et al.
patent: 5763164 (1998-06-01), Calenoff
patent: 5876728 (1999-03-01), Kass et al.
patent: 6322989 (2001-11-01), Cohen
patent: 6387639 (2002-05-01), Posner et al.
patent: 0 236 606 (1992-06-01), None
patent: 2 395 270 (2004-05-01), None
patent: 09 189702 (1997-07-01), None
patent: WO 92/13065 (1992-08-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 93/21529 (1993-10-01), None
patent: WO 94/23728 (1994-10-01), None
patent: WO 96/00084 (1996-01-01), None
patent: WO 96/03502 (1996-02-01), None
patent: WO 96 03502 (1996-02-01), None
patent: WO 97/14794 (1997-04-01), None
patent: WO 98/55872 (1998-12-01), None
patent: WO 99/58978 (1999-11-01), None
patent: WO 00/26668 (2000-05-01), None
Karanikas, et al., J Clin Invest Dec. 1, 1997;100(11):2783-92.
Sandrin et al, Glycoconjugate Journal, 1997, vol. 14, pp. 97-105.
Apostolopoulos et al, Nature Medicine, 1998, vol. 4, pp. 315-320.
Ben-Mahrez et al (British Journal of Cancer, 1988).
Hehir et al (Journal of Surgical Oncology, 1993, vol. 54, pp. 207-210).
Pavelic et al (Anticancer Research, 1991, vol. 11, pp. 1421-1428).
Sahin et al (PNAS, 1995, vol. 92, pp. 11810-11813).
Scanlan et al (International Journal of Cancer, 1998, vol. 76, pp. 652-658).
Petrakou et al (International Journal of oncology, 1997, vol. 11, suppl., p. 902).
Koterra et al (Cancer Research, 1994, vol. 54, pp. 2856-2860).
abstract of Mensdorf-Pouilly et al (Anticancer Research, Nov.-Dec. 1997, vol. 17, p. 4184).
Denton et al (Cancer Letters, 1993, vol. 70, pp. 143-150).
Zisman et al (Journal of Urology, 1995, vol. 154, pp. 1052-1055).
Deguchi et al (Int Arch Allergy Appl Immunol, 1988, vol. 87, pp. 313-316).
Abstract of Yamamoto et al (Proc Amer Soc Cancer Res, Mar. 1997, p. 564).
Disis et al (Journal of Clinical Oncology, 1997, vol. 15, pp. 3363-3367).
Croce et al (Cancer Immunol. Immunother., 1995, vol. 40, pp. 132-137).
Green et al (European Journal of Cancer, 1994, vol. 30A, pp. 580-584).
Stearns et al (Breast Cancer Research and Treatment, Feb. 8, 1998, vol. 52, pp. 239-259).
Kawahara (Cancer, 1986, vol. 58, pp. 2008-2012).
Abstract of Hayes (Anticancer Drugs, 1995, vol. 6, suppl. 2, pp. 26-27).
Abstract of Pandha et al (Cancer Gene Therapy, 1997, vol. 4, No. 5, p. 310).
Bhatti et al et al (Journal of Tumor Marker Oncology, (Summer-1994), vol. 9, pp. 125-131).
Chinni et al (Clinical Cancer Research, 1997, vol. 3, pp. 1557-1564).
Lidner et al (Biotechniques, 1997, vol. 22, pp. 140-149).
Definition of “moncyte” in On-line Medical Dictionary downloaded on Feb. 5, 2005 from url.cancerweb.ncl.ac.uk.
Voet et al., Biochemistry, 1990, pp. 1096 and 1098.
Voet et al., Biochemistry, 1990, p. 78.
Janeway et al., Immunobiology, 5thed.
Rao, S.G., “Detection of Human Ovarian Tumor Associated Antigens by Autologous Antibodies Isolated from Ovarian Carcinoma Ascites Fluid”;Proceedings of the American Association for Cancer Research Annual Meeting, 1987, vol. 28, p. 358.
Fishman, P., “Application of autoantibodies to cancer therapy: A new concept”,The 9thInternational Congress of Immunology, 1995, p. 664.
Kutteh, W.H., et al., “Immunologic characterization of tumor markers in human ovarian cancer cell lines”;Journal of the Society for Gynecologic Investigation, 1996, vol. 3, No. 4, pp. 216-222.
Petrarca, C., “Human Antibodies Against the Polymorphic Epithelial Mucin in Ovarian Cancer Patients Recognise a Novel Sequence in the Tandem Repeat Region”;European Journal of Cancer, vol. 32A, No. 12, pp. 2155-2163, 1996.
Von Mensdorff-Pouilly, S., “Humoral Immune Response to Polymorphic Epithelial Mucin (MUC-1) inpatients with Benign and Malignant Breast Tumours”;European Journal of Cancer, vol. 32A, No. 8, pp. 1325-1331, 1996.
Gourevitch, MM; “Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients”;British Journal of Cancer, 72, pp. 934-938; (1995).
Agrawal et al.; “Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2”; Nature Medicine; vol. 4, No. 1, Jan. 1998; pp. 43-49.
Asano et al..; “Presence of anti-AFT-antibody producing B cells in peripheral blood lymphocyte of hepatocellular carcinoma patient”; Nippon Shokakibyo Gakkai Zasshi; Feb. 1984; 81(2):278.
Carlsson, Hans E.; “Titration of Antibodies to Salmonella O Antigens by Enyzme-Linked Immunosorbent Assay”; Infection and Immunity, Nov. 1972, vol. 6, No. 5, pp. 703-708.
Dahlberg, T.; “Enzyme-Linked Immunosorbent Assay for Titration ofHaemophilus influenzaeCapsular and O Antigen Antibodies”; Journal of Clinical Microbiology, Aug. 1980, vol. 12, No. 2, pp. 185-192.
Jalanko et al.; “Immunochemical properties of alpha-fetoprotein (AFP) and antibodies to autologous AFT”; Immunol. Commun. 1978, vol. 7, No. 2, pp. 209-222.
Jerome et al.; “A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis”; Cancer Immunol Immunother; 1997; p. 355-360.
Munoz et al.; “New experimental criteria for optimization of solid-phase antigen concentration and stability in ELISA”; J. Immunol. Methods; 1986; 20;137-44
Muraki et al.; “Assessment of serum CYFRA 21-1 in lung cancer”; Cancer; Apr. 1996; 77(7): 1274-7.
Rasmussen et al.; “An ELISA for the detection of anti-neutrophil cytoplasm antibodies (ANCA)”; J. Immunol. Methods; Feb. 1990; 127(1):139-45.
Stieber et al.; “CYFRA 21-1. A new marker in lung cancer”; Cancer; Aug. 1993; 72(3):707-13.
Stockert et al.; “A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens”; J. Exp. Med.; vol. 187, No. 8, Apr. 20, 1998; pp. 1349-1354.
Taylor-Papadimitriou; “Report on the First International Workshop on Carcinoma-Associated Mucins”; Int. J. Cancer: 49, 1-5 (1991).
Tsai et al.; “Relationship of serum alpha-fetoprotein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma”; Gastroenterol Jpn.; Jun. 1990; 25(3):338-93.
Zielen et al.; “Simple determination of polysaccharide specific antibodies by means of chemically modified ELISA plates”; J. Immunol. Methods; Jun. 1996; 193(1):1-7.
Angelopoulou et al.; “Detection of the TP53 Tumour Suppressor Gene Product and p53 Auto-antibodies in the Ascites of Women with Ovarian Cancer”; European Journal of Cancer; vol. 33, No. 1, Jan. 1997, pp. 115-121.
Ibrahim et al.; “Expression of biomarkers (pt3, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2
ew and the proliferation cell nuclear antigen) in oropharyngeal squamous cell carcinomas”; Oral Oncoloby, vol. 35, No. 3, May 1999, pp. 302-313.
Jais et al.; “Association of serum antibodies against p53 protein with poor survival in patients with Zollinger-Ellison syndrome”; Gastroenterology; vol. 114, No. 1, Jan. 1998, pp. 37-43.
Soussi; “The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy

Affiliated with

Also associated with

Rating

Tumour markers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumour markers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumour markers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3970688